DexCare vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
DexCare raised $192M including a $75M Series C in June 2024 led by ICONIQ Growth; its health system platform has surpassed 3M patient visits scheduled; health system customers became investors.
About
DexCare is a Seattle-based digital health company that spun out of Providence in 2021. It provides a patient access and demand management platform that helps health systems balance patient demand against available care capacity — across virtual, in-person, and urgent care settings. Its AI-driven matching engine connects patients to the most appropriate care option (right care, right time, right location), improving both patient access and health system revenue per available slot.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.